Oncology Central

Key mechanism that drives hormone therapy resistance in prostate cancer uncovered

A study in mice and human prostate cancer cells has demonstrated that blocking the protein IL-23, which is produced by granulocytic myeloid-derived suppressor cells, can restore tumor cells sensitivity to hormone therapy. The findings were recently published in Nature.
To view restricted content, please:




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.